Back to Search
Start Over
SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?
- Source :
- Journal of Clinical Immunology; Oct2021, Vol. 41 Issue 7, p1502-1506, 5p
- Publication Year :
- 2021
-
Abstract
- Non-stimulated STAT1 levels in CD8+ T cells before and during SARS-CoV-2 infection (A); pSTAT1 levels in CD8 + T cells pre- and post-stimulation with IFN before and during SARS-CoV-2 infection (B). In addition, serum levels of IL6, IFN , and CXCL10 were elevated during infection, supporting the ability of the patient to develop an inflammatory response even under ruxolitinib therapy. Although increased total STAT1 levels were documented, hyperphosphorylation of STAT1 was not observed during the complete follow-up, proposing ruxolitinib to be effective in controlling cytokine hyperresponsiveness typically found in STAT1 GOF patients, even in the context of SARS-CoV-2 infection. [Extracted from the article]
- Subjects :
- STAT proteins
SARS-CoV-2
RUXOLITINIB
COVID-19
MONONUCLEAR leukocytes
INFECTION
Subjects
Details
- Language :
- English
- ISSN :
- 02719142
- Volume :
- 41
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Journal of Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 152535155
- Full Text :
- https://doi.org/10.1007/s10875-021-01081-9